

A MODEL BASED ANALYSIS OF IPEC DOSING OF PTX IN RATS

P.Colin¹, L. De Smet², C. Vervae², J.-P. Remon², W. Ceelen³, K. Boussey¹, J. Van Bocxlaer¹, A. Vermeulen¹


¹ Laboratory of Medical Biochemistry and Clinical Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Belgium

² Laboratory of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Ghent University, Belgium

³ Laboratory of Experimental Surgery, Ghent University Hospital, Belgium


1. Introduction - IPEC treatment

- Intraperitoneal Chemotherapy after cytoreductive surgery improves survival in patients with peritoneal carcinomatosis
- Animal models are used to evaluate IPEC treatment modalities (**treatment duration** and **perfusate concentration**)
- Focus on PK (extent of **systemic exposure** and **tumor accumulation**) and PD (**exposure - response** relationship) of paclitaxel following normothermic (37°C, 45 min) IPEC administration of Taxol®




Pelz et al. A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis. BMC Cancer 2005;5:56

2. Data collection



3. PKPD model



4. Results

